1344697-16-0

Upstream product

• 1344700-12-4 1-{[(2S)-1-ethoxy-2-methyl-3-(methylamino)-1,3-dioxopropan-2-yl](methyl)carbamolyl}-4-iodobenzene 
• 1344700-62-4 (2S)-N,2-dimethyl-2-[methyl(4-{[4-(1,4-oxazepan-4-ylmethyl)phenyl]ethynyl}benzoyl)amino]-N'-(tetrahydro-2H-pyran-2-yloxy)propanediamide 
• 1344700-13-5 1-{[(2S)-2-carboxy-1-(methylamino)-1-oxopropan-2-yl](methyl)carbamolyl}-4-iodobenzene 
• 1344700-14-6 (2S)-2-(4-iodo-N-methylbenzamide)-N¹,2-dimethyl-N³-((tetrahydro-2H-pyran-2-yl)oxy)malonamide 
• 1344700-60-2 (2S)-2-[{4-[(4-formylphenyl)ethynyl]benzoyl}(methyl)amino]-N,2-dimethyl-N'-(tetrahydro-2H-pyran-2-yloxy)propanediamide 
• 63697-96-1 4-Ethynylbenzaldehyde 

Relevant academic research and scientific papers

NOVEL HYDROXAMIC ACID DERIVATIVE

Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug resistant bacteria. Provided is a hydroxamic acid derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof: